Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma:A case report

作     者：Si-Cong Chen Dong-Heng Ma Jia-Jian Zhong 

作者机构：Hepatobiliary and Pancreatic SurgeryHuazhong University of Science and Technology Union Shenzhen HospitalShenzhen 518052Guangdong ProvinceChina 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2023年第11卷第27期

页      面：6579-6586页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Esophageal squamous cell carcinoma Toripalimab Anlotinib Complete response Case report 

摘      要：BACKGROUND Toripalimab and anlotinib have shown good response in esophageal cancer,with high objective response rate and progression free ***,they have been approved as second-line or above-line therapy for advanced or unresectable esophageal *** of these two drugs may have synergistic effects,but evidence of which is *** SUMMARY Here,we report on a 73-year-old male,newly diagnosed with advanced esophageal squamous cell carcinoma(ESCC),who received a combination of toripalimab and *** response was achieved after treatment for 3 mo and remission was maintained up to 14 *** The combination therapy of toripalimab and anlotinib is a promising treatment for unresectable ESCC and related clinical trials are warranted.